Get the Stockscreener App
0.92
7.43%
-0.0738
Oncolytics Biotech Inc stock is traded at $0.92, with a volume of 329.94K.
It is down -7.43% in the last 24 hours and down -1.10% over the past month.
Oncolytics Biotech Inc is a clinical-stage biopharmaceutical company. The company is focused on the discovery and development of pharmaceutical products for the treatment of cancers that have not been treated with therapeutics. It is developing pelareorep, an immunotherapeutic agent that improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatment. The other projects in the company's pipeline include, Bracelet-1 for treatment of Breast Cancer, Goblet cohort-1, Goblet cohort-5 for treatment of Gastro-Intestinal Cancer among others.
See More
Previous Close:
$0.9938
Open:
$0.98
24h Volume:
329.94K
Relative Volume:
0.56
Market Cap:
$73.17M
Revenue:
-
Net Income/Loss:
$-20.31M
P/E Ratio:
-2.7479
EPS:
-0.3348
Net Cash Flow:
$-21.07M
1W Performance:
+1.57%
1M Performance:
-1.10%
6M Performance:
-7.07%
1Y Performance:
-31.85%
1-Day Range:
$0.92
$0.99
1-Week Range:
$0.88
$1.06
52-Week Range:
$0.7101
$1.53
Oncolytics Biotech Inc Stock (ONCY) Company Profile
Compare ONCY with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ONCY
Oncolytics Biotech Inc
|
0.92 | 73.17M | 0 | -20.31M | -21.07M | -0.2645 |
|
VRTX
Vertex Pharmaceuticals Inc
|
399.99 | 103.35B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
703.63 | 77.35B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.12 | 37.04B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
235.68 | 30.14B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
111.33 | 26.97B | 3.30B | -501.07M | 1.03B | -2.1146 |
Oncolytics Biotech Inc Stock (ONCY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-06-22 | Initiated | Maxim Group | Buy |
| Feb-17-21 | Initiated | H.C. Wainwright | Buy |
Oncolytics Biotech Inc Stock (ONCY) Latest News
Oncolytics Biotech (TSE:ONC) Stock Passes Above 200 Day Moving Average – Here’s Why - Defense World
Oncology In Focus: How Emerging Therapies Are Reshaping Cancer Treatment - Barchart
Oncology in Focus: How Emerging Therapies Are Reshaping Cancer Treatment - Benzinga
The Immunotherapy Boom: What It Means For The Future Of Cancer Treatment - MENAFN.COM
The Immunotherapy Boom: What It Means for the Future of Cancer Treatment - Baystreet.ca
Achievements and Progress Heading into 2025 for Oncology Treatments and Therapies Fuel an Optimistic Outlook - GlobeNewswire
Stocks In Play: Oncolytics Biotech Inc - Barchart
How Cutting-Edge Immunotherapies Are Redefining Cancer Treatment Options - Barchart
Oncolytics Biotech® Highlights 2024 Achievements and Prepares for an Influential 2025 with Promising Breast and GI Cancer Data (PR Newswire) - Aktiellt
Oncology Advancements Accelerate Amid Rising Early-Onset Cancer Diagnoses - Lelezard
From Crisis to Opportunity: How Advances in Immunotherapy Are Shaping the Oncology Sector - Baystreet.ca
Oncolytics Biotech (TSE:ONC) Trading Up 14.5%Should You Buy? - MarketBeat
From Crisis To Opportunity: How Advances In Immunotherapy Are Shaping The Oncology Sector - MENAFN.COM
Oncolytics Biotech® to Present Promising Pelareorep Data in Pancreatic and Anal Cancers at ASCO GI Symposium - The Malaysian Reserve
Coty Inc (COTY-N) QuotePress Release - The Globe and Mail
Stocks In Play: Oncolytics Biotech Inc. - Barchart
Oncolytics Bio (ONC-T) QuotePress Release - The Globe and Mail
Early-Onset Cancer Trends Spark Interest In Promising Oncology Pipelines - MENAFN.COM
Oncolytics Biotech Inc. - Baystreet.ca
Early-Onset Cancer Trends Spark Interest in Promising Oncology Pipelines - Baystreet.ca
Oncolytics Biotech Inc - Baystreet.ca
Promising Data for Treating Gastrointestinal Cancer Leading to Hopeful Advancements for Pancreatic & Anal Cancers - GlobeNewswire
Oncolytics Biotech's SWOT analysis: pelareorep progress boosts stock outlook - Investing.com
Oncolytics Biotech (TSE:ONC) Sets New 12-Month LowWhat's Next? - MarketBeat
Oncolytics Biotech® to Participate in Fireside Chats at Two Investment Conferences in September - The Eastern Progress Online
Oncolytics Biotech (NASDAQ:ONCY) Trading Down 2.1%Should You Sell? - MarketBeat
Oncolytics Biotech® to Host Conference Call to Discuss Third Quarter Financial Results and Recent Operational Highlights - The Eastern Progress Online
Oncolytics Biotech's SWOT analysis: pela's potential buoys speculative stock By Investing.com - Investing.com Nigeria
Oncolytics Biotech's SWOT analysis: pela's potential buoys speculative stock - Investing.com India
Oncolytics Biotech's SWOT analysis: cancer drug developer's stock faces pivotal year - Investing.com
Oncolytics Biotech Inc. Reports Completion of Initial Safety Phase Enrollment for GOBLET Trial?s New Pancreatic Cancer Cohort - Marketscreener.com
Stocks In Play: Oncolytics Biotech Inc By Baystreet.ca - Investing.com Canada
Oncolytics Biotech® Reports Completion of Initial Safety Phase Enrollment for GOBLET Trial's New Pancreatic Cancer Cohort - Barchart
Oncolytics Biotech® Reports Completion of Initial Safety Phase E - GuruFocus.com
Oncolytics Biotech Inc Stock (ONCY) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.03%
0.20%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):